Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Point-of-Care Diagnostics & Biosensors Europe 2018

Jean-Manuel Segura's Biography



Jean-Manuel Segura, Professor, University of Applied Sciences and Arts Western Switzerland Valais

Jean-Manuel Segura is professor of chemistry at the University of Applied Sciences and Arts Western Switzerland since 2008. He graduated in 1995 from EPF Lausanne in chemical engineering and obtained his Ph.D. in 2000 from ETH Zürich in physical chemistry followed by post-doctoral and group leader positions at Leiden University, at EPFL and at the Ludwig Institute, His current research interests include the development of novel integrated point-of-care in-vitro diagnostics assays, the exploration of novel “smart” sensor molecules such as fluorescent aptamers or supramolecular biosensors as well as the application of paper-based devices for rapid immunoassays.

Jean-Manuel Segura Image

Micro-Analytical Devices for Therapeutic-Drug Quantification in Whole Blood at the Point of Care

Wednesday, 6 June 2018 at 15:00

Add to Calendar ▼2018-06-06 15:00:002018-06-06 16:00:00Europe/LondonMicro-Analytical Devices for Therapeutic-Drug Quantification in Whole Blood at the Point of CarePoint-of-Care Diagnostics and Biosensors Europe 2018 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com

Therapeutic Drug Monitoring (TDM) allows for personalized dosage during therapeutic treatments and is often mandatory for modern potent drugs against cancer, infections or in organ transplantation cases. A prototypical example is the antibiotics tobramycin, which is often prescribed to neonates in case of bacterial infection and requires TDM to ensure efficacy while avoiding oto- and nephrotoxicity. Currently, the process of TDM is demanding for the patient as several milliliters of blood are required, is slow and costly due to the transfer of sample to a central laboratory, and suffers of limited efficacy owing to the difficulty to interpret the results for a non-specialist. In a first project, we aimed at circumventing these problems by developing a point-of-care device enabling the quantification of therapeutic drugs in blood using fluorescence-polarization immunoassays (FPIA). We showed that FPIA can be downsized with reduced requirements in blood sample (only 1 µL) and number of steps, without compromising assay reliability, and can be successfully integrated within paper-like micro-chambers. Whole-blood measurements were made possible by further using the paper-like micro-chambers as a filtering device. The final TDM point-of-care test requires minute amounts of blood and minimal handling steps. In a second project, we addressed cases where single measurements are not sufficient like during cancer chemotherapies. Here patients are subjects to administration of high doses of drugs during long periods of time which can last up to several days. Ideally, drug doses should be continuously adjusted to keep blood concentrations within the therapeutic range. This requires regular blood tests, typically every 15 to 30 minutes. I will present the latest results of a project aiming to develop an autonomous monitoring system able to continuously measure drug concentrations in blood.


Add to Calendar ▼2018-06-05 00:00:002018-06-06 00:00:00Europe/LondonPoint-of-Care Diagnostics and Biosensors Europe 2018Point-of-Care Diagnostics and Biosensors Europe 2018 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com